UBS Raises Price Target on Horizon Pharma (HZNP) After Traveling with Management
Tweet Send to a Friend
UBS reiterates a Buy rating on Horizon Pharma (NASDAQ: HZNP), and raised the price target to $40.00 (from $32.00), after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
